Advertisement

Andrea Wang-Gillam, MD, PhD

Articles

Dr. Wang-Gillam on Next Steps With Defactinib Combo in Pancreatic Ductal Adenocarcinoma

May 5th 2020

Andrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.

Dr. Wang-Gillam on Results of a Phase 1 Study With Defactinib in Pancreatic Ductal Adenocarcinoma

April 28th 2020

Andrea Wang-Gillam, MD, PhD, discusses the results of a phase 1 study with defactinib in patients with pancreatic ductal adenocarcinoma.

Dr. Wang-Gillam on PF-04136309 Plus FOLFIRINOX in Pancreatic Adenocarcinoma

January 17th 2015

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a combination treatment of PF-04136309 with FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma (PC).

Dr. Wang-Gillam Discusses the Mechanism of Action of MM-398

August 4th 2014

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses the mechanism of action of MM-398, a novel encapsulation of irinotecan in a long-circulating nanoliposome.

Dr. Wang-Gillam Discusses the NAPOLI-1 Trial in Pancreatic Cancer

June 28th 2014

Andrea Wang-Gillam, MD, PhD, from the Siteman Cancer Center, discusses the trial design and results of the phase III NAPOLI-1 trial that examined MM-398 with 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer following progression on gemcitabine-based therapy.

Advertisement
Advertisement